136 related articles for article (PubMed ID: 17323523)
1. Drug-induced hyperkalaemia is frequent.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17323523
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.
Prescrire Int; 2004 Apr; 13(70):58. PubMed ID: 15148978
[No Abstract] [Full Text] [Related]
3. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M
Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422
[TBL] [Abstract][Full Text] [Related]
4. [Let's read the domestic literature. ACE-inhibitors and spironolactone-induced hyperkalemia].
Radó J
Orv Hetil; 2002 Aug; 143(31):1868; author reply 1868. PubMed ID: 12187583
[No Abstract] [Full Text] [Related]
5. [Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers].
Roskiewicz F; Andriamanana I; Gras-Champel V; Andrejak M; Massy ZA
Nephrol Ther; 2007 Jun; 3(3):89-95. PubMed ID: 17540310
[TBL] [Abstract][Full Text] [Related]
6. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
[TBL] [Abstract][Full Text] [Related]
7. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
Gottlieb S
BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321896
[No Abstract] [Full Text] [Related]
8. Inducing hyperkalemia by converting enzyme inhibitors and heparin.
Durand D; Ader JL; Rey JP; Tran-Van T; Lloveras JJ; Bernadet P; Suc JM
Kidney Int Suppl; 1988 Sep; 25():S196-7. PubMed ID: 3184611
[No Abstract] [Full Text] [Related]
9. [Ineffective atrial pacing and cardiac arrest in a 80-year old woman with hyperkalemia].
Lelakowski J; Czunko A; Majewski J; Pasowicz M; Małecka B; Bednarek J
Pol Merkur Lekarski; 2005 May; 18(107):566-7. PubMed ID: 16161957
[TBL] [Abstract][Full Text] [Related]
10. Diabetes may be independent risk factor for hyperkalaemia.
Jarman PR; Mather HM
BMJ; 2003 Oct; 327(7418):812. PubMed ID: 14525902
[No Abstract] [Full Text] [Related]
11. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
Konopa J; Bułło B; Rutkowski B
Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone in patients with heart failure.
Vanpee D; Swine C
N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
[No Abstract] [Full Text] [Related]
13. The safety of spironolactone treatment in patients with heart failure.
Anton C; Cox AR; Watson RD; Ferner RE
J Clin Pharm Ther; 2003 Aug; 28(4):285-7. PubMed ID: 12911680
[TBL] [Abstract][Full Text] [Related]
14. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
[TBL] [Abstract][Full Text] [Related]
15. [A patient with severe hyperkalaemia -- an emergency after RALES].
Nürnberger J; Daul A; Philipp T
Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
[TBL] [Abstract][Full Text] [Related]
16. Drug safety in patients with heart failure.
Juurlink DN; Hansten PD
Arch Intern Med; 2005 Jan; 165(1):118. PubMed ID: 15642888
[No Abstract] [Full Text] [Related]
17. Cutaneous adverse effects of angiotensin-II receptor antagonists.
Prescrire Int; 2007 Feb; 16(87):21. PubMed ID: 17326283
[TBL] [Abstract][Full Text] [Related]
18. [Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
Kauffmann R; Orozco R; Venegas JC
Rev Med Chil; 2005 Aug; 133(8):947-52. PubMed ID: 16163434
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
Berry C; McMurray J
Am J Med; 2001 Nov; 111(7):587. PubMed ID: 11705445
[No Abstract] [Full Text] [Related]
20. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).
Hauben M; Reich L; Gerrits CM; Madigan D
Drug Saf; 2007; 30(12):1143-9. PubMed ID: 18035866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
